Patents by Inventor Zhidan Wu

Zhidan Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8334111
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: December 18, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ruth E. Gimeno, Rosana Kapeller-Libermann, Zhidan Wu, Brian K. Hubbard
  • Publication number: 20120177661
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Application
    Filed: March 20, 2012
    Publication date: July 12, 2012
    Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
  • Publication number: 20120076729
    Abstract: The present application describes methods for treating and/or preventing cancer or a cancer symptom, e.g., AMPK-related cancers, in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an FGF, e.g., FGF21, or an FGF agonist, or a pharmaceutical composition comprising the same.
    Type: Application
    Filed: June 2, 2010
    Publication date: March 29, 2012
    Inventors: Dinh Le Mary Chau, Jesper Gromada, Zhidan Wu
  • Publication number: 20120003233
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Application
    Filed: January 28, 2011
    Publication date: January 5, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
  • Patent number: 7910346
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: March 22, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ruth E. Gimeno, Rosana Kapeller-Libermann, Zhidan Wu, Brian K. Hubbard
  • Publication number: 20100104584
    Abstract: The invention discloses suitable gene and polypeptide targets for the development of new therapeutics to treat, prevent or ameliorate conditions associated with mitochondrial dysfunction. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor, as well as to a method to identify compounds with therapeutic usefulness to treat conditions associated with mitochondrial dysfunction.
    Type: Application
    Filed: February 14, 2008
    Publication date: April 29, 2010
    Inventors: Jian Chen, Dan Garza, Hao Li, Susan C. Stevenson, Zhidan Wu
  • Publication number: 20100035339
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Application
    Filed: April 30, 2009
    Publication date: February 11, 2010
    Inventors: Ruth E. GIMENO, Zhidan WU, Rosana KAPELLER-LIBERMANN, Brian K. HUBBARD
  • Publication number: 20090281191
    Abstract: Use of a ERR? agonist Or pharmaceutically acceptable salt thereof, for the prevention, delay of progression or the treatment of diabetes, insulin resistance, metabolic disease/metabolic syndrome, dyslipdemia, obesity, overweight, Neurodegenerative diseases such as Parkinson's disease. Alzheimer's disease, Huntington's disease or improvement of exercise endurance capacity.
    Type: Application
    Filed: May 2, 2007
    Publication date: November 12, 2009
    Inventors: Shamina M. Rangwala, Susan C. Stevenson, Zhidan Wu
  • Publication number: 20090269332
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Application
    Filed: February 17, 2009
    Publication date: October 29, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
  • Patent number: 7527962
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: May 5, 2009
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
  • Publication number: 20070166748
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection, with obesity disorders are also disclosed.
    Type: Application
    Filed: March 9, 2007
    Publication date: July 19, 2007
    Inventors: Ruth GIMENO, Zhidan WU, Rosana Kapeller-Libermann, Brian Hubbard
  • Publication number: 20060183210
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Application
    Filed: December 7, 2005
    Publication date: August 17, 2006
    Inventors: Ruth Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian Hubbard
  • Publication number: 20060134752
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Application
    Filed: February 6, 2006
    Publication date: June 22, 2006
    Inventors: Ruth Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian Hubbard
  • Patent number: 6908987
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: June 21, 2005
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Patent number: 6872391
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: March 29, 2005
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Publication number: 20030229204
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 16, 2003
    Publication date: December 11, 2003
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Publication number: 20030170691
    Abstract: The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.
    Type: Application
    Filed: December 19, 2002
    Publication date: September 11, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ruth E. Gimeno, Zhidan Wu, Rosana Kapeller-Libermann, Brian K. Hubbard
  • Publication number: 20030073819
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 27, 2002
    Publication date: April 17, 2003
    Applicant: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Patent number: 6525178
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: February 25, 2003
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
  • Patent number: 6426411
    Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: July 30, 2002
    Assignee: Dana-Farber Cancer Institute
    Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant